Fig. 2From: A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary diseaseChange from baseline in trough FEV1. a D28a trough FEV1 and b trough FEV1 on D1, D15, D16 and D28. Data presented as LS mean ± SE. *p < 0.001 versus placebo. Abbreviations: FEV1: forced expiratory volume in 1 s; LS: least squares; Rev.: revefenacin; SE: standard error. aD28 trough FEV1 measured on D29Back to article page